Existing drugs have limited efficacy against the rising threat of drug-resistant TB, have significant side effects, and must be given in combinations of four to six drugs for at least 6 months for drug-sensitive TB and up to 24 months for drug-resistant TB. The long treatment duration has led to increased patient noncompliance with therapy. This, in turn, drives the development of additional drug resistance in a spiral that has resulted in some forms of TB being currently untreatable by existing drugs. New antitubercular drugs in development, particularly those with mechanisms of action that are different from existing first- and second-line TB drugs, are anticipated to be effective against both drug-sensitive and drug-resistant TB. SQ109 is a new TB drug candidate with a novel mechanism of action that was safe and well tolerated in Phase I and early Phase II clinical trials. We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug.
Existing drugs have limited efficacy against the rising threat of drug-resistant pan class="Chemical">TB, have significant side effects, and must be given in combinations of four to six drugs for at least 6 months for drug-sensitive n>n class="Chemical">TB and up to 24 months for drug-resistant TB. The long treatment duration has led to increased patient noncompliance with therapy. This, in turn, drives the development of additional drug resistance in a spiral that has resulted in some forms of TB being currently untreatable by existing drugs. New antitubercular drugs in development, particularly those with mechanisms of action that are different from existing first- and second-line TB drugs, are anticipated to be effective against both drug-sensitive and drug-resistant TB. SQ109 is a new TB drug candidate with a novel mechanism of action that was safe and well tolerated in Phase I and early Phase II clinical trials. We describe herein the identification, development and characterization of SQ109 as a promising new antitubercular drug.
Authors: S Sreevatsan; K E Stockbauer; X Pan; B N Kreiswirth; S L Moghazeh; W R Jacobs; A Telenti; J M Musser Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191
Authors: Oluseye K Onajole; Sphelele Sosibo; Patrick Govender; Thavendran Govender; Paul D van Helden; Glenn E M Maguire; Kata Mlinarić-Majerski; Ian Wiid; Hendrik G Kruger Journal: Chem Biol Drug Des Date: 2011-10-24 Impact factor: 2.817
Authors: Kapil Tahlan; Regina Wilson; David B Kastrinsky; Kriti Arora; Vinod Nair; Elizabeth Fischer; S Whitney Barnes; John R Walker; David Alland; Clifton E Barry; Helena I Boshoff Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: Jason E Farley; Malathi Ram; William Pan; Stacie Waldman; Gail H Cassell; Richard E Chaisson; Karin Weyer; Joey Lancaster; Martie Van der Walt Journal: PLoS One Date: 2011-07-22 Impact factor: 3.240
Authors: Peter C Ray; Margaret Huggett; Penelope A Turner; Malcolm Taylor; Laura A T Cleghorn; Julie Early; Anuradha Kumar; Shilah A Bonnett; Lindsay Flint; Douglas Joerss; James Johnson; Aaron Korkegian; Steven Mullen; Abraham L Moure; Susan H Davis; Dinakaran Murugesan; Michael Mathieson; Nicola Caldwell; Curtis A Engelhart; Dirk Schnappinger; Ola Epemolu; Fabio Zuccotto; Jennifer Riley; Paul Scullion; Laste Stojanovski; Lisa Massoudi; Gregory T Robertson; Anne J Lenaerts; Gail Freiberg; Dale J Kempf; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Kevin D Read; Simon R Green; Paul G Wyatt; Tanya Parish Journal: ACS Omega Date: 2021-01-13
Authors: John T Williams; Elizabeth R Haiderer; Garry B Coulson; Kayla N Conner; Edmund Ellsworth; Chao Chen; Nadine Alvarez-Cabrera; Wei Li; Mary Jackson; Thomas Dick; Robert B Abramovitch Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Jim Werngren; Maria Wijkander; Nasrin Perskvist; V Balasubramanian; Vasan K Sambandamurthy; Camilla Rodrigues; Sven Hoffner Journal: Antimicrob Agents Chemother Date: 2014-04-28 Impact factor: 5.191
Authors: Marie H Foss; Sovitj Pou; Patrick M Davidson; Jennifer L Dunaj; Rolf W Winter; Sovijja Pou; Meredith H Licon; Julia K Doh; Yuexin Li; Jane X Kelly; Rozalia A Dodean; Dennis R Koop; Michael K Riscoe; Georgiana E Purdy Journal: ACS Infect Dis Date: 2016-05-13 Impact factor: 5.084